Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT07348107
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. (ATARI-PDAC)
A Phase 1 Study of ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-L1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
Sponsor: BeiGene (Canada) ULC
Conditions
Advanced Pancreatic Ductal Adenocarcinoma
Interventions
ATRA Arsenic Trioxide (ATO) Gemcitabine Nab-paclitaxel Tislelizumab
Updated 1 time since 2026 Last updated: Jan 9, 2026 Started: Feb 15, 2026 Primary completion: Mar 31, 2027 Completion: Mar 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Advanced Pancreatic Ductal Adenocarcinoma and is currently actively recruiting participants. BeiGene (Canada) ULC leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- BeiGene (Canada) ULC
- Daniel Breadner
- SDK Therapeutics, Inc.
Data source: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
For direct contact, visit the study record on ClinicalTrials.gov .